Annie Luetkemeyer, MD
Professor
Medicine
School of Medicine

Education & Training

Show all (6) Hide

• Fellowship Infectious Diseases University of California, San Francisco 2007
• Advance Training in Clinical Research University of California, San Francisco 2006
• Internal Medicine University of California, San Francisco 2003
• Internal Medicine University of California, San Francisco 2002
• MD Medicine Harvard Medical School 1999
• AB American Studies Stanford University 1994

Interests

Show all (7) Hide

• DoxyPEP
• COVID-19 treatment and prevention
• HIV therapeutic strategies
• Hepatitis C
• Hepatitis Elimination
• Viral hepatitis
• Sexually Transmitted Infections

Websites

Show all (3) Hide

• @@annieluet on Twitter (twitter.com)
• End Hep C SF (endhepcsf.org)
• Open Clinical Studies at SFGH ID division (hividgm.ucsf.edu)

Publications (57)

Top publication keywords:
Antiviral AgentsSofosbuvirTuberculosisDrug Resistance, ViralHepatitis C, ChronicHepatitis CRifampinBenzoxazinesCoinfectionTuberculosis, PulmonaryHIV InfectionsAntitubercular AgentsImidazolesDoxycyclineHepacivirus

• Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial.
  JAMA network open 2023 Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC
• Postexposure Doxycycline for Sexually Transmitted Infections. Reply.
  The New England journal of medicine 2023 Luetkemeyer AF, Cannon C, Celum C
• Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case.
  Open forum infectious diseases 2023 Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, El Sahly HM, Jain MK, …
• Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial.
  Research square 2023 Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Anderson E, Walter E, Novak R, Rupp R, Jackson L, Babu T, Kottkamp A, Luetkemeyer A, Immergluck L, Presti …
• Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.
  JAMA network open 2022 Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola…

Show all (52 more) Hide

• Remdesivir for the Treatment of Covid-19 - Final Report.
  The New England journal of medicine 2020 Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, …
• Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence.
  Alimentary pharmacology & therapeutics 2020 Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G
• Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials …
• A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome.
  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2019 Silva CAM, Graham B, Webb K, Ashton LV, Harton M, Luetkemeyer AF, Bokatzian S, Almubarak R, Mahapatra S, Hovind L, Kendall MA, Havlir D, Belisle JT, De Groote MA
• Localized US Efforts to Eliminate Hepatitis C.
  Infectious disease clinics of North America 2018 Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, Huriaux E, Facente SN, Luetkemeyer A, Waters P, Graham CS
• Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
  Liver international : official journal of the International Association for the Study of the Liver 2017 Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS, RESCUE and ACTG A5348 study investigators
• Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
  Hepatology (Baltimore, Md.) 2017 Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin…
• Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome.
  Open forum infectious diseases 2017 Woodworth MH, Marquez C, Chambers H, Luetkemeyer A
• Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis.
  Journal of clinical medicine 2017 Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF, AIDS Clinical Trials Group A5295, …
• Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.
  Open forum infectious diseases 2017 Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, …
• Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017 Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M, …
• Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.
  Topics in antiviral medicine 2017 Wyles DL, Luetkemeyer AF
• CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis.
  Topics in antiviral medicine 2017 Luetkemeyer AF, Wyles DL
• Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients.
  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2017 Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina JM, Xu D, Srinivasan S, Portsmouth S
• Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
  Annals of internal medicine 2016 Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, …
• Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells.
  PloS one 2016 Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA
• A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries.
  BMC infectious diseases 2016 Godfrey C, Tauscher G, Hunsberger S, Austin M, Scott L, Schouten JT, Luetkemeyer AF, Benson C, Coombs R, Swindells S, HIV Network Coordinating (HANC) TB Diagnostic Laboratory Working Division of AIDS,…
• CROI 2016: Viral Hepatitis and Liver Fibrosis.
  Topics in antiviral medicine 2016 Luetkemeyer AF, Wyles DL
• Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda.
  The Pediatric infectious disease journal 2016 Marquez C, Chamie G, Achan J, Luetkemeyer AF, Kyohere M, Okiring J, Dorsey G, Kamya MR, Charlebois ED, Havlir DV
• 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P
• Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, …
• The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
  Journal of acquired immune deficiency syndromes (1999) 2016 Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N, ACTG A5281 …
• Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
  The New England journal of medicine 2015 Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, …
• Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
  The New England journal of medicine 2015 Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison …
• Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification.
  Journal of clinical microbiology 2015 Lee SA, Plett SK, Luetkemeyer AF, Borgo GM, Ohliger MA, Conrad MB, Cookson BT, Sengupta DJ, Koehler JE
• CROI 2015: Highlights of Viral Hepatitis Therapy.
  Topics in antiviral medicine 2015 Luetkemeyer AF, Wyles DL
• Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW, Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams
• Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
  JAMA 2014 Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres …
• Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
  Antimicrobial agents and chemotherapy 2014 Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW, AIDS Clinical Trials Group A5306 Study Team
• CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy.
  Topics in antiviral medicine 2014 Luetkemeyer AF, Havlir DV, Currier JS
• HIV-associated central nervous system tuberculosis.
  Seminars in neurology 2014 Chamie G, Marquez C, Luetkemeyer A
• Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.
  Journal of acquired immune deficiency syndromes (1999) 2014 Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J, Adult AIDS Clinical Trials Group A5221 Study Team
• Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
  Journal of acquired immune deficiency syndromes (1999) 2014 Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ, A5239 Team
• Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.
  Journal of clinical microbiology 2014 Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, Qasba SS, Sanchez J, Havlir DV, Grinsztejn B, Sanne IM, Firnhaber C, Adult AIDS Clinical Trials Group A5255 Study Team
• Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial.
  HIV clinical trials 2013 Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG
• Household ventilation and tuberculosis transmission in Kampala, Uganda.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2013 Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED
• Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013 Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F, Adult AIDS Clinical Trials Group A5221 Study Team
• CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.
  Topics in antiviral medicine 2013 Luetkemeyer AF, Havlir DV, Currier JS
• Complications of HIV disease and antiretroviral therapy.
  Topics in antiviral medicine 2012 Luetkemeyer AF, Havlir DV, Currier JS
• Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.
  Journal of acquired immune deficiency syndromes (1999) 2011 Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG
• Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
  The New England journal of medicine 2011 Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, …
• CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
  American journal of respiratory and critical care medicine 2011 Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, …
• Tuberculosis drug development: ensuring people living with HIV are not left behind.
  American journal of respiratory and critical care medicine 2011 Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV
• Complications of HIV disease and antiretroviral therapy.
  Topics in antiviral medicine 2011 Luetkemeyer AF, Havlir DV, Currier JS
• Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States.
  Topics in HIV medicine : a publication of the International AIDS Society, USA 2010 Luetkemeyer AF
• Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2010 Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED
• Tuberculosis as part of the natural history of HIV infection in developing countries.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010 Chamie G, Luetkemeyer A, Charlebois E, Havlir DV
• Complications of HIV disease and antiretroviral treatment.
  Topics in HIV medicine : a publication of the International AIDS Society, USA 2010 Luetkemeyer AF, Havlir DV, Currier JS
• Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.
  American journal of respiratory and critical care medicine 2007 Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV
• Antiretroviral therapy and TB.
  Tropical doctor 2006 Swaminathan S, Luetkemeyer A, Srikantiah P, Lin R, Charlebois E, Havlir DV
• Clinical presentation and course of acute hepatitis C infection in HIV-infected patients.
  Journal of acquired immune deficiency syndromes (1999) 2006 Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M
• Willing and able? Provision of medication for abortion by future internists.
  Women's health issues : official publication of the Jacobs Institute of Women's Health 2005 Schwarz EB, Luetkemeyer A, Foster DG, Weitz TA, Lindes D, Stewart FH